Zobrazeno 21 - 30
of 678
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Mary S. Guirguis, Beatriz Adrada, Miral Patel, Frances Perez, Rosalind Candelaria, Wei Yang, Jia Sun, Rania M. Mohamed, Medine Boge, H. T. Carisa Le-Petross, Jessica Leung, Gary J. Whitman, Deanna L. Lane, Marion E. Scoggins, Tanya Moseley, Benjamin Musall, Jason White, Sanaz Pashapoor, Peng Wei, Jong Bum Son, Ken-Pin Hwang, Bikash Panthi, Mark Pagel, Lei Huo, Kelly K. Hunt, Elizabeth Ravenberg, Alastair M. Thompson, Jennifer K. Litton, Vicente Valero, Debu Tripathy, Stacy Moulder, Clinton Yam, Jingfei Ma, Gaiane Rauch
Publikováno v:
Cancer Research. 83:P1-05
PURPOSE Triple-negative breast cancer (TNBC) is a heterogeneous disease with variable response to neoadjuvant therapy (NAT). Pathologic complete response (pCR) has become a prognostic marker for overall and disease-free survival. The aim of this stud
Autor:
Xuemei Xie, Marwa Manai, Jon A. Fuson, Troy Pearson, Dileep R. Rampa, Debu Tripathy, Jangsoon Lee, Naoto T. Ueno
Publikováno v:
Cancer Research. 83:P4-08
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC subtypes, the luminal androgen receptor (LAR) subtype expresses high levels of androgen receptor (AR), tends to be less proliferative, and generall
Autor:
Robin M. Lally, Rachael L. Schmidt, Gisele Tlusty, Elizabeth K. Arthur, Laura K. Flora, Jessica L. Krok-Schoen, Jessica T. Jones, Meagan Whisenant, Abbey Kaler, Debu Tripathy, Leorey Saligan, Marilyn Hammer, Austin Barr, Lindsey Jackson, Jennifer Loftis, Kelly J. Brassil
Publikováno v:
Cancer Research. 83:OT2-06
Background: Women with breast cancer account for the largest cohort (23%) of over 18 million cancer survivors in the United States. Of the nearly 4 million breast cancer survivors, many, including individuals with metastatic breast cancer, will requi
Autor:
Xiaoding Hu, Yun Xiong, Emilly S. Villodre, Juhee Song, Ganiraju C Manyam, Moises J Tacam, Jing Wang, Chandra Bartholomeusz, Debu Tripathy, Naoto T. Ueno, Wendy Woodward, Savitri Krishnamurthy, Junjie Chen, Bisrat Debeb
Publikováno v:
Cancer Research. 83:GS5-08
Background: Inflammatory breast cancer (IBC) is a highly aggressive form of breast cancer with rapid onset and a strong propensity to spread to distant organs. Five-year overall survival (OS) rates remain poor, in part because of the high risk of bra
Autor:
Irene Kang, Jamie K. Forschmiedt, Michelle M. Loch, William E. Barlow, Danika L. Lew, Julie R. Gralow, Funda Meric-Bernstam, Kathy S. Albain, Daniel F. Hayes, Nancy U. Lin, Edith A. Perez, Lori J. Goldstein, Priya Rastogi, Anne F. Schott, Steven Shak, Priyanka Sharma, Jieling Miao, Debu Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi, Kevin Kalinsky, N. Lynn Henry
Publikováno v:
Cancer Research. 83:GS1-04
Introduction: Breast cancer treatment is associated with cancer-related cognitive impairment (CRCI). However, the differential effect of endocrine therapy (ET) vs chemotherapy followed by endocrine therapy (CET), including the impact of menopausal st
Publikováno v:
Cancer Research. 83:P4-08
BACKGROUND HER2-negative (HER2−) breast cancer (BC) subtypes, such as luminal A and triple-negative breast cancer (TNBC), express human trophoblast cell-surface antigen 2 (Trop-2). A high level of Trop-2 expression is associated with a poor prognos
Autor:
Eve Rodler, Priyanka Sharma, William E Barlow, Julie R Gralow, Shannon L Puhalla, Carey K Anders, Lori Goldstein, Debu Tripathy, Ursa A Brown-Glaberman, Thu-Tam Huynh, Christopher S Szyarto, Andrew K Godwin, Harsh B Pathak, Elizabeth M Swisher, Marc R Radke, Kirsten M Timms, Danika L Lew, Jieling Miao, Lajos Pusztai, Daniel F Hayes, Gabriel N Hortobagyi
Publikováno v:
The Lancet Oncology. 24:162-174
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Autor:
Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogene
Externí odkaz:
https://doaj.org/article/3b5c30a996d54c2086cfff5a285a1014
Autor:
Nour Abuhadra, Ryan Sun, Jennifer K. Litton, Gaiane M. Rauch, Clinton Yam, Jeffrey T. Chang, Sahil Seth, Roland Bassett, Bora Lim, Alastair M. Thompson, Elizabeth Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Jason White, Elizabeth Ravenberg, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul A. Sahin, Vicente Valero, William Fraser Symmans, Debu Tripathy, Stacy Moulder, Lei Huo
Publikováno v:
Cancers, Vol 14, Iss 5, p 1323 (2022)
High stromal tumor-infiltrating lymphocytes (sTILs) are associated with an improved pathologic complete response (pCR) and survival in triple-negative breast cancer (TNBC). We hypothesized that high baseline sTILs would have a favorable prognostic im
Externí odkaz:
https://doaj.org/article/952af2308a3544ecb401c3451546048a
Autor:
Akshara Singareeka Raghavendra, George Kypriotakis, Maher Karam-Hage, Seokhun Kim, Mazen Jizzini, Kareem S. Seoudy, Jason D. Robinson, Carlos H. Barcenas, Paul M. Cinciripini, Debu Tripathy, Nuhad K. Ibrahim
Publikováno v:
Cancers, Vol 14, Iss 6, p 1464 (2022)
Background: Smoking negatively affects overall survival after successful breast cancer (BC) treatment. We hypothesized that smoking cessation would improve survival outcomes of BC patients who were smokers at the time of diagnosis. Methods: This was
Externí odkaz:
https://doaj.org/article/9eaa892203a34c66bf4ce7b0e6f521b4